BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou Y, Zhou Y, Yang M, Wang K, Liu Y, Zhang M, Yang Y, Jin C, Wang R, Hu R. Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway. Redox Biol 2019;22:101131. [PMID: 30735911 DOI: 10.1016/j.redox.2019.101131] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Grattarola M, Cucci MA, Roetto A, Dianzani C, Barrera G, Pizzimenti S. Post-translational down-regulation of Nrf2 and YAP proteins, by targeting deubiquitinases, reduces growth and chemoresistance in pancreatic cancer cells. Free Radic Biol Med 2021;174:202-10. [PMID: 34364982 DOI: 10.1016/j.freeradbiomed.2021.08.006] [Reference Citation Analysis]
2 Bellomo F, De Leo E, Taranta A, Giaquinto L, Di Giovamberardino G, Montefusco S, Rega LR, Pastore A, Medina DL, Di Bernardo D, De Matteis MA, Emma F. Drug Repurposing in Rare Diseases: An Integrative Study of Drug Screening and Transcriptomic Analysis in Nephropathic Cystinosis. Int J Mol Sci 2021;22:12829. [PMID: 34884638 DOI: 10.3390/ijms222312829] [Reference Citation Analysis]
3 Qin JJ, Cheng XD, Zhang J, Zhang WD. Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: a systematic review. Cell Commun Signal 2019;17:121. [PMID: 31511020 DOI: 10.1186/s12964-019-0435-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
4 Zhang X, Zhou C, Yang Y, Liu H, Wang S, Ding X, Wang H. The Discovery of Potential MDM2 Inhibitors: A Combination of Pharmacophore Modeling, Virtual Screening, Molecular Docking Studies, and in vitro/in vivo Biological Evaluation. ChemMedChem 2021. [PMID: 34806333 DOI: 10.1002/cmdc.202100517] [Reference Citation Analysis]
5 Zhou Y, Zhou Y, Wang K, Li T, Zhang M, Yang Y, Wang R, Hu R. ROCK2 Confers Acquired Gemcitabine Resistance in Pancreatic Cancer Cells by Upregulating Transcription Factor ZEB1. Cancers (Basel) 2019;11:E1881. [PMID: 31783584 DOI: 10.3390/cancers11121881] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
6 Wang Y, Ma Q, Zhang S, Liu H, Zhao B, Du B, Wang W, Lin P, Zhang Z, Zhong Y, Kong D. Digoxin Enhances the Anticancer Effect on Non-Small Cell Lung Cancer While Reducing the Cardiotoxicity of Adriamycin. Front Pharmacol 2020;11:186. [PMID: 32180730 DOI: 10.3389/fphar.2020.00186] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
7 Barrera G, Cucci MA, Grattarola M, Dianzani C, Muzio G, Pizzimenti S. Control of Oxidative Stress in Cancer Chemoresistance: Spotlight on Nrf2 Role. Antioxidants (Basel) 2021;10:510. [PMID: 33805928 DOI: 10.3390/antiox10040510] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Lin H, Qiao Y, Yang H, Nan Q, Qu W, Feng F, Liu W, Chen Y, Sun H. Small molecular Nrf2 inhibitors as chemosensitizers for cancer therapy. Future Med Chem 2020;12:243-67. [PMID: 31950858 DOI: 10.4155/fmc-2019-0285] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
9 Karaś K, Sałkowska A, Dastych J, Bachorz RA, Ratajewski M. Cardiac glycosides with target at direct and indirect interactions with nuclear receptors. Biomed Pharmacother 2020;127:110106. [PMID: 32248001 DOI: 10.1016/j.biopha.2020.110106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Ngoi NY, Liew AQ, Chong SJF, Davids MS, Clement MV, Pervaiz S. The redox-senescence axis and its therapeutic targeting. Redox Biol 2021;45:102032. [PMID: 34147844 DOI: 10.1016/j.redox.2021.102032] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Li X, Wang Z, Zhang S, Yao Q, Chen W, Liu F. Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis. Oncol Lett 2021;21:352. [PMID: 33747209 DOI: 10.3892/ol.2021.12613] [Reference Citation Analysis]
12 Tan Z, Xu J, Zhang B, Shi S, Yu X, Liang C. Hypoxia: a barricade to conquer the pancreatic cancer. Cell Mol Life Sci 2020;77:3077-83. [PMID: 31907561 DOI: 10.1007/s00018-019-03444-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
13 Liu P, Ma D, Wang P, Pan C, Fang Q, Wang J. Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2. Cell Death Dis 2021;12:20. [PMID: 33414469 DOI: 10.1038/s41419-020-03331-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
14 Yang J, Xu J, Zhang B, Tan Z, Meng Q, Hua J, Liu J, Wang W, Shi S, Yu X, Liang C. Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer. Int J Mol Sci 2021;22:10944. [PMID: 34681603 DOI: 10.3390/ijms222010944] [Reference Citation Analysis]
15 Wang J, Sun D, Huang L, Wang S, Jin Y. Targeting Reactive Oxygen Species Capacity of Tumor Cells with Repurposed Drug as an Anticancer Therapy. Oxid Med Cell Longev 2021;2021:8532940. [PMID: 34539975 DOI: 10.1155/2021/8532940] [Reference Citation Analysis]
16 Cykowiak M, Krajka-kuźniak V. Role of Nrf2 in Pancreatic Cancer. Antioxidants 2022;11:98. [DOI: 10.3390/antiox11010098] [Reference Citation Analysis]
17 Sun X, Zhang X, Zhai H, Zhang D, Ma S. Chicoric acid (CA) induces autophagy in gastric cancer through promoting endoplasmic reticulum (ER) stress regulated by AMPK. Biomed Pharmacother 2019;118:109144. [PMID: 31545234 DOI: 10.1016/j.biopha.2019.109144] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
18 Zou J, Su H, Zou C, Liang X, Fei Z. Ginsenoside Rg3 suppresses the growth of gemcitabine-resistant pancreatic cancer cells by upregulating lncRNA-CASC2 and activating PTEN signaling. J Biochem Mol Toxicol 2020;34:e22480. [PMID: 32104955 DOI: 10.1002/jbt.22480] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
19 Zhou Y, Wang K, Zhou Y, Li T, Yang M, Wang R, Chen Y, Cao M, Hu R. HEATR1 deficiency promotes pancreatic cancer proliferation and gemcitabine resistance by up-regulating Nrf2 signaling. Redox Biol 2020;29:101390. [PMID: 31785531 DOI: 10.1016/j.redox.2019.101390] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
20 Kang G, Hu M, Ren H, Wang J, Cheng X, Li R, Yuan B, Balan Y, Bai Z, Huang H. VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo. Cancer Biol Med 2021:j. [PMID: 33830713 DOI: 10.20892/j.issn.2095-3941.2020.0568] [Reference Citation Analysis]
21 Wang Y, Hou Y, Hou L, Wang W, Li K, Zhang Z, Du B, Kong D. Digoxin exerts anticancer activity on human nonsmall cell lung cancer cells by blocking PI3K/Akt pathway. Biosci Rep 2021;41:BSR20211056. [PMID: 34549269 DOI: 10.1042/BSR20211056] [Reference Citation Analysis]
22 Liu Y, Chang M, Hu Z, Xu X, Wu W, Ning M, Hang T, Song M. Danggui Buxue Decoction enhances the anticancer activity of gemcitabine and alleviates gemcitabine-induced myelosuppression. J Ethnopharmacol 2021;273:113965. [PMID: 33639205 DOI: 10.1016/j.jep.2021.113965] [Reference Citation Analysis]
23 van der Merwe M, van Niekerk G, Fourie C, du Plessis M, Engelbrecht AM. The impact of mitochondria on cancer treatment resistance. Cell Oncol (Dordr) 2021. [PMID: 34244972 DOI: 10.1007/s13402-021-00623-y] [Reference Citation Analysis]
24 Fouzder C, Mukhuty A, Kundu R. Kaempferol inhibits Nrf2 signalling pathway via downregulation of Nrf2 mRNA and induces apoptosis in NSCLC cells. Arch Biochem Biophys 2021;697:108700. [PMID: 33271149 DOI: 10.1016/j.abb.2020.108700] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
25 Zhou Y, Zhou Y, Wang K, Li T, Yang M, Wang R, Chen Y, Cao M, Hu R. Flumethasone enhances the efficacy of chemotherapeutic drugs in lung cancer by inhibiting Nrf2 signaling pathway. Cancer Lett 2020;474:94-105. [PMID: 31954771 DOI: 10.1016/j.canlet.2020.01.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]